Skip to main content
. 2019 Oct 16;9:14871. doi: 10.1038/s41598-019-51207-8

Table 1.

Patient characteristics categorized by the median EPO level.

Variables All patients Low EPO High EPO P value
n 290 145 145
EPO, IU/L 14.4 (10.2–22.8) 10.2 (8.4–12.1) 22.8 (17.9–33.6) <0.01
Age, years 71 (64–77) 70 (63–76) 72 (66–78) 0.04
Male sex 176 (61) 88 (61) 88 (61) 1.00
BMI, kg/m2 23.5 (21.1–26.8) 23.1 (20.7–25.8) 23.9 (21.5–27.8) 0.04
History of CVD 135 (47) 61 (42) 74 (51) 0.13
Diabetic retinopathy 119 (41) 68 (47) 51 (35) 0.04
Smoking 44 (15) 20 (14) 24 (17) 0.51
SBP, mmHg 130 (122–138) 129 (122–138) 130 (122–137) 0.73
Hemoglobin A1c, % 6.9 (6.3–7.4) 6.9 (6.4–7.4) 6.9 (6.3–7.5) 0.75
LDL-cho, mg/dL 95 (79–116) 98 (79–116) 95 (78–117) 0.82
eGFR, mL/min/1.73 m2 53 (40–67) 49 (40–63) 56 (40–71) 0.08
Corrected Ca, mg/dL 9.2 (9.0–9.4) 9.3 (9.0–9.4) 9.2 (9.0–9.4) 0.93
Albumin, g/dL 4.1 (3.9–4.4) 4.2 (3.9–4.4) 4.1 (3.8–4.3) 0.04
CRP, mg/dL 0.06 (0.01–0.15) 0.06 (0.01–0.11) 0.06 (0.01–0.22) 0.12
Hemoglobin, g/dL 11.8 (11.0–12.5) 11.9 (11.5–12.6) 11.4 (10.8–12.4) <0.01
TSAT, % 23.4 (15.9–31.1) 25.9 (20.2–32.1) 19.7 (10.9–29.1) <0.01
Ferritin, ng/dL 69 (26–214) 88 (46–141) 32 (14–103) <0.01
UACR, mg/g Cre 60 (16–320) 74 (20–359) 47 (14–276) 0.11
u-LFABP, mg/g Cre 5.1 (2.3–14.2) 5.6 (2.5–15.7) 4.4 (2.1–11.8) 0.17
FGF23, pg/mL 32 (27–45) 34 (27–49) 33 (27–42) 0.31
25D, ng/mL 8 (5–13) 9 (5–13) 7 (5–14) 0.31
ACEI/ARB 177 (61.0) 93 (64.1) 84 (57.9) 0.28
Statin 113 (40) 61 (42) 52 (37) 0.34
Insulin 150 (53) 77 (54) 73 (52) 0.77
OHA 213 (74.7) 103 (71.0) 110 (75.9) 0.35
Outcome
eGFR slope, mL/min/1.73 m2/year −1.3 (−3.6–1.0) −1.7 (−4.0–0.4) −0.8 (−3.3–1.4) 0.02

Data are expressed as median (interquartile range) or n (%). EPO, erythropoietin; BMI, body mass index; CVD, cardiovascular disease; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; Ca, calcium; CRP, C-reactive protein; TSAT, transferrin saturation; Cre, urine creatinine; UACR, urine albumin-to-creatinine ratio; u-LFABP, urinary liver-type fatty acid-binding protein; FGF23, fibroblast growth factor 23; 25D, 25-hydroxyvitamin D; ACEI/ARB, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; OHA, oral hypoglycemic agents.